Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., appointed Harald Hampel vice president, global medical affairs and Michael Irizarry vice president, clinical research. Hampel will be responsible for creating and overseeing the company's global Alzheimer's disease (AD)/dementia medical strategies. Read More
Tessa Therapeutics Pte Ltd., of Singapore, reported preclinical data showing TT-16, its combination immunotherapy integrating CAR T-cell therapy and oncolytic adenovirus expressing immunomodulatory molecules, resulted in durable response in various HER2-positive solid tumor models. Read More
PERTH, Australia – Australia's largest venture capital firm, Brandon Capital Partners, has raised AU$210 million (US$147 million) for a new medical research fund that will invest in early stage discoveries linked to Medical Research Commercialization Fund (MRCF) members, a network of more than 50 medical research institutes and hospitals across Australia and New Zealand. Read More
SHANGHAI - Uncertainties over U.S.-China trade relations seem not to have stunted enthusiasm for partnering among a record crowd expected at this year's Chinabio Partnering Forum this week. The annual confab is expected to draw about 1,400 attendees, about 60% from China, with the rest about evenly split between participants from ex-China Asian countries and Western delegates representing U.S. and Europe. Read More
Researchers have discovered that the synaptic protein Bassoon accumulated in the neurons of mice with experimental autoimmune encephalitis, the closest animal model to multiple sclerosis (MS), causing neuronal damage in much the same way that protein aggregates damage neurons in neurodegenerative diseases. Read More
HONG KONG – The Korean government plans to invest KRW2.93 trillion (US$2.52 billion) this year to give the biomedical and pharmaceutical industries, as well as medical technologies a boost, according to the Ministry of Science and ICT (Information & Communications Technology). The most significant investments are likely to go toward bioscience and medicine, which will account for 54% and 18% of the budget, respectively. Read More
PERTH, Australia – Drug safety advisories around the globe are often inconsistent, and Australia's Therapeutic Goods Administration (TGA) is one of the most inconsistent compared to its peers, according to a review of drug regulators in Australia, Canada, the U.K. and the U.S. over the last decade. Read More
LONDON – The clamp-down on Chinese investment in U.S. technology companies is prompting investors to look elsewhere, with European biotech startups emerging as one of the beneficiaries. Read More
The U.S. Trade Representative's (USTR) 2019 Special 301 Report shows some progress is being made, but a lot of work remains to be done to end the global free-loading as the U.S. continues to pick up the lion's share of the cost of innovation in the drug and device sectors. Read More
HONG KONG – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. has filed an IPO with the Hong Kong Stock Exchange (HKEX), making it the latest pre-revenue applicant for listing on the HKEX, which already has seven pre-profit biotech players listed. Read More
